Sumitomo Mitsui Trust Group Inc. Buys 167,596 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sumitomo Mitsui Trust Group Inc. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 11.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,614,313 shares of the company's stock after purchasing an additional 167,596 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.42% of Moderna worth $107,885,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC grew its holdings in Moderna by 26.8% during the first quarter. Empowered Funds LLC now owns 4,276 shares of the company's stock valued at $456,000 after purchasing an additional 904 shares during the period. Atomi Financial Group Inc. bought a new stake in Moderna in the 1st quarter valued at about $225,000. Sei Investments Co. lifted its holdings in Moderna by 16.4% during the first quarter. Sei Investments Co. now owns 84,910 shares of the company's stock valued at $9,048,000 after purchasing an additional 11,977 shares during the last quarter. US Bancorp DE boosted its position in Moderna by 19.5% during the first quarter. US Bancorp DE now owns 23,107 shares of the company's stock worth $2,462,000 after purchasing an additional 3,771 shares during the period. Finally, Avantax Advisory Services Inc. increased its stake in shares of Moderna by 53.3% in the first quarter. Avantax Advisory Services Inc. now owns 5,035 shares of the company's stock worth $537,000 after purchasing an additional 1,750 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,930 shares of company stock valued at $217,170 over the last ninety days. 15.70% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. TD Cowen reduced their price objective on shares of Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a research note on Friday, September 13th. Sanford C. Bernstein began coverage on Moderna in a report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. Leerink Partners decreased their price target on Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a research report on Tuesday, September 17th. Bank of America reduced their price objective on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating for the company in a research note on Friday, September 13th. Finally, Oppenheimer cut shares of Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $93.18.

Moderna Trading Down 1.4 %

Shares of NASDAQ:MRNA traded down $0.58 on Thursday, reaching $41.56. 5,065,144 shares of the company traded hands, compared to its average volume of 4,586,129. Moderna, Inc. has a 52 week low of $40.24 and a 52 week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The business's 50-day simple moving average is $59.96 and its 200 day simple moving average is $97.80. The stock has a market capitalization of $15.99 billion, a P/E ratio of -7.24 and a beta of 1.69.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.39) earnings per share. As a group, equities analysts anticipate that Moderna, Inc. will post -9.34 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.